PLUS THERAPEUTICS, INC.

CNSide Diagnostics, a wholly-owned subsidiary of Cerenome, Inc., announced an in-network provider agreement with Health Care Service Corporation (HCSC). This partnership adds approximately 27.3 million covered lives, bringing CNSide's total contracted access to 153 million commercial and Medicare Advantage covered lives. This achievement surpasses the company's 2026 full-year objective of 150 million covered lives ahead of schedule, aiming to expand patient access and drive physician adoption of the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay.

Plus Therapeutics, Inc. announced its corporate rebrand to Cerenome, Inc., effective August 3, 2026. Concurrently, the company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "CNSY." This strategic rebrand signifies the company's evolution from a therapeutics-focused organization into an integrated CNS oncology company, combining precision diagnostics, targeted therapeutics, and proprietary data within a single entity to improve outcomes for CNS cancer patients.

Plus Therapeutics, Inc. announced it will rebrand as Cerenome, Inc. and trade under the new Nasdaq ticker symbol CNSY, effective August 3, 2026. The company also announced it will present two posters and host a sponsored symposium at the 2026 SNO/ASCO CNS Metastases Conference. The presentations will highlight its ReSPECT-LM clinical development program and CNSide® cerebrospinal fluid diagnostic platform, focusing on improving detection, treatment, and monitoring of CNS metastases.

Plus Therapeutics' wholly-owned subsidiary, CNSide Diagnostics, LLC, announced a regional agreement with Medical Mutual, effective July 1, 2026. This partnership expands coverage for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay to approximately 1.2 million people in Ohio and Kentucky, bringing the total contracted coverage to about 127 million people. The CNSide® assay has been used in over 11,000 tests since 2020, showing high sensitivity and specificity. Additionally, Plus Therapeutics will change its corporate name to Cerenome, Inc. and its Nasdaq ticker symbol to CNSY, effective August 3, 2026.

Plus Therapeutics highlighted that its CNSide CSF assay platform aligns with the updated NCCN Clinical Practice Guidelines for Central Nervous System Cancers, reinforcing the value of sensitive CSF-based tools for diagnosing and monitoring leptomeningeal metastases. The company's CNSide platform has expanded its U.S. commercial foundation, achieving approximately 126 million contracted covered lives, including new agreements with Blue Shield of California and Elevance Health. Plus Therapeutics also announced it will change its corporate name to Cerenome, Inc. and trade under the Nasdaq ticker CNSY effective August 3, 2026.

Plus Therapeutics announced a comprehensive business update, including a rebrand to Cerenome and a change of its Nasdaq ticker to CNSY, effective August 3, 2026. The company affirmed its 2026 milestones guidance, highlighting significant commercial progress for its CNSide® Diagnostics platform, which now covers approximately 126 million lives. Additionally, Plus Therapeutics provided updates on its REYOBIQ™ clinical and manufacturing advancements, and its new AI strategy.

Plus Therapeutics, Inc. announced that its wholly-owned subsidiary, CNSide Diagnostics, LLC, has signed a national agreement with Elevance Health, Inc. This deal, effective May 1, 2026, extends coverage for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay to approximately 45.4 million people across the United States. This expansion brings the total contracted coverage for the CNSide® CSF TCE assay to 126 million people, significantly broadening access to its diagnostic platform for leptomeningeal metastases.

Plus Therapeutics, Inc. announced it will host a business update conference call and webcast on June 30, 2026, at 8:30 a.m. ET. Management will provide updates on the CNSide® diagnostic launch, the integrated development plan for its lead drug Reyobiq, and its CNS oncology strategy. The call will also cover the company's native artificial intelligence development plans, with the CEO expressing excitement about progress across all three areas.

Plus Therapeutics, Inc. has entered into an Equity Distribution Agreement with Canaccord Genuity LLC, enabling the company to sell up to $17,350,000 of its common stock. The shares will be offered "at the market" on the Nasdaq Capital Market, with the agent receiving a 3.0% commission. The net proceeds from this offering are intended to be used for general corporate purposes and working capital.

Plus Therapeutics, Inc. announced that its wholly owned subsidiary, CNSide Diagnostics, LLC, has received accreditation from the College of American Pathologists (CAP). This accreditation, recognized as the "gold standard" in laboratory accreditation, follows a rigorous on-site inspection of CNSide Diagnostics' Houston-based clinical laboratory. The company expects this milestone to reinforce clinical confidence, advance payer engagement for broader coverage and reimbursement, facilitate health system adoption, and enable future menu expansion for its CNSide® CSF Assay Platform.